Introduction
Enzymes infections are more common in clinical settings, especially in populations with low immune function, long-term use of antibiotics or chronic diseases. Primary health care institutions, as the front line of health care services, are responsible for the first and basic treatment of a large number of patients and for the rational treatment of yeast infection with the precision of the medication, which is important for increasing the patient ‘ s healing rate, reducing medical costs and preventing the production of drug-resistant strains.
II. Strengthening capacity to diagnose pathogens
1. Regulation of specimen collection and detection: Primary level medical personnel should be skilled in the correct method of collecting specimens, e.g. in cases of suspected yeast infection, skin mucous infections should collect crumbs, skin mosaics or circulants from the pathogen; vaginal yeast infections should collect vaginal secretions; deep tissue infections should obtain tissue or body fluid samples through sterile operations. The collection is carried out in a timely manner to ensure the quality and timeliness of the specimen and to avoid inaccuracies in the results of pathogen tests due to the improper collection of specimens or delays in their delivery.
2. Upgrading laboratory levels: Primary-level medical institutions should gradually be equipped with the necessary fungal detection equipment, such as microscopes, fungi incubators, etc., to carry out fungi smears and culture screening, which is the basis for the diagnosis of yeast infections. At the same time, the active promotion of new, rapid and accurate detection techniques, such as fungi antigens, anti-medical test kits, and molecular biology detection methods (e.g. PCR techniques) provides a strong basis for the identification of yeast species in a short period of time.
III. Optimizing drug treatment programmes
1. Reasonable choice of anti-foulbacterial drugs: selection of appropriate anti-foulbacterial drugs according to the type of pathogens, the area of infection, the severity of the disease and the individual circumstances of the patient. In the case of mild skin mucus yeast infections, such as ecstasy in the vaginal pseudoplasm, the use of external antifluorinated drugs such as Crocodium, Miconium, etc., may be highly active and less adverse; in the case of patients with deep yeast infections or more serious conditions, the choice of systematic antifluorinated drugs such as fluconium, its broad spectrum, high bioavailability and safety, and its wider application at the grass-roots level, but for certain non-white peptophilus infections, it may be necessary to select, on the basis of the sensitive results of the drug, Icoconol, Voliconol, or Vibactin.
2. Precise determination of the dose and course of treatment of the drug: Determination of the dose of the drug in strict accordance with the drug instructions and the relevant guidelines, so as to avoid the failure of treatment or the adverse effects of excessive doses due to insufficient doses. At the same time, the treatment process is determined on the basis of factors such as the area of infection, the elimination of pathogens and the patient ‘ s immune status. The general skin mucous infection treatment is relatively short, while the treatment of patients with a deep tissue infection or low immune function is relatively long, and the effects of the treatment need to be closely monitored and adjusted in due course to prevent the recurrence of premature withdrawals.
IV. Improving the professionalism of health personnel
1. Continuing education and training: Medical staff are regularly organized to attend training courses, academic lectures and case discussions on the treatment of yeast infections, and specialists from higher hospitals are invited to give instruction and guidance on the pathology, epidemiology, diagnostic methods and progress of drug treatment of yeast, and the knowledge system of primary health-care staff is constantly updated to improve their ability to diagnose and treat yeast infections.
2. Establishment of mechanisms for the participation of clinical pharmacists: clinical pharmacists reach out to grass-roots medical institutions, participate in clinical drug treatment teams, assist doctors in developing rational drug use programmes, educate patients about drug use, monitor adverse drug responses, further improve the level of rational drug use in primary health-care institutions through a close combination of pharmacological expertise and clinical practice, and guarantee the safety and effectiveness of the treatment of yeast infections.
V. Strengthening patient management and health education
1. Individualized treatment and follow-up: in the course of treatment, full consideration is given to the age of the patient, the underlying disease and the function of the liver and kidney, individualized treatment programmes are developed, and follow-up visits are strengthened, in order to keep abreast of changes in the patient ‘ s condition, the dependence of the treatment and the adverse effects of the drug, and to adapt the treatment to the results of the follow-up to ensure its accuracy and effectiveness.
2. Health education campaigns: In many ways, through information boards, health lectures and information materials, patients are provided with information on the prevention and treatment of yeast infections, including the causes of infection, means of transmission, methods of prevention and care in the treatment process, so as to increase their self-protection and treatment compliance, reduce the incidence of re-emergence of yeast infections and promote their rehabilitation.
While primary health-care institutions face many challenges in the rational and accurate treatment of yeast infection, comprehensive measures such as strengthening the diagnostic capacity of pathogens, optimizing drug treatment programmes, improving the professional literacy of health-care providers and strengthening patient management and health education will enable them to continuously improve the level of treatment of yeast infection in primary health-care institutions, provide better quality, efficient and safe medical care for patients, promote the health development of primary health care and contribute to the implementation of the China strategy for healthy health.
